Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis Shifts in APAC healthcare

The Asia-Pacific (APAC) healthcare industry is undergoing rapid transformation with a dramatic shift in consumer behaviour and expectations, opening up growth opportunities across diagnostics, regenerative medicine, medical tourism and digital health.

The positive growth is fuelled by increasing adoption of new technology, innovative healthcare access programs, and delivery of care outside traditional hospital settings. Frost & Sullivan projects a revenue growth of over 12% in 2018, making APAC one of the fastest growing regions for the healthcare industry in the world.

Frost & Sullivan’s recent analysis, Asia-Pacific Healthcare Outlook, looks at a number of predictions for the APAC healthcare industry.

“Through digital transformation healthcare companies are introducing service-orientated business models, and direct-to-consumer care delivery platforms in the region,” said Natasha Gulati, industry manager, transformational health, Frost & Sullivan. 

“Meanwhile new approaches to health and wellness, like “omics” based health advisory and gamification are gaining market momentum,” she added. 
Gulati recommends players focus on personalisation, combined with consumer empowerment, as a key ingredient for disease prevention and patient wellness. Innovative companies active in this space include Prudential, iCarbonX, and Healthi which are moving toward personalised wellness intervention through the introduction of direct-to-consumer gene sequencing, and Thorne Research and Imagene Labs which are about to make available personalised over-the counter nutritional supplements and skin care products on a subscription model. 

Six key trends spurring growth opportunities in the APAC healthcare industry include: the rise of new payment models, especially those tied to value-based outcomes; fast-tracked innovative therapeutic products, development and penetration of regenerative medicine, biosimilars, and genetics; technology innovation with rapid development in areas like Artificial Intelligence, mHealth, and virtual reality; the development of personalisation combined with consumer empowerment for prevention and wellness; the adoption of wireless real-time monitoring, aided by analytics, as the clinical community aims for further efficiency and outcome-based approaches; and the rapid deployment of cloud solutions to increase IT efficiency in non-clinical departments.

 “An important global trend that is currently missing in APAC is the introduction of value-and outcomes-based payment and reimbursement models. Industry suppliers, including IT vendors, medical technology companies and pharmaceuticals, are partnering with public and private payers to introduce outcomes-based reimbursement models for expensive therapeutic products and services in other parts of the world,” noted Gulati.

Posted on: 14/05/2018 UTC+08:00


News

Metro Pacific Hospital Holdings, the healthcare unit of industrial conglomerate Metro Pacific Investments, is finally expected to push the button on its Philippine Stock Exchange IPO next year.
MedAdvisor will form a 50:50 joint venture based in Singapore with Zuellig Pharma to commercialise MedAdvisor’s medication management platform in Asia.
Thermo Fisher Scientific, the world leader in serving science, today opened its first Bioprocess Design Centre in Shanghai, China. The new centre is part of a strategy to establish a centre of excellence where Thermo Fisher scientists can connect and collaborate with biologic developers to design optimal bioprocessing solutions.
Mitsui & Co will acquire an additional 16% of the shares of one of Asia’s largest private hospital groups, IHH Healthcare, from Malaysia’s Khazanah Nasional.
Mach7 Technologies, a company specialising in innovative data management solutions for healthcare providers, has raised A$3 million (US$2.2 million) via a private placement.
Pacific Edge is to raise NZ$12 million (US$8.2 million) in a share placement and via a share purchase plan.
We Doctor Holdings, China's leading technology-enabled medical and healthcare solutions platform, joined hands today in Guangzhou with the Guangdong Women and Children's Hospital and Health Institute to launch China's first provincial-level internet hospital for women and children.
Singapore-based medtech startup Ark has raised US$40 million in Series A funding round led by Venturecraft shareholders and joined by Gaorong Capital – formerly known as Banyan Capital. It is one of the largest Series A rounds closed by a southeast Asian firm.



Analysis

French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.
For too many companies, a stock market flotation is the be all and end all. Chief executives have spent months on roadshows, locked up with bankers and lawyers. Understandably they think that they can now rest on their laurels.
Today is the launch of Asia Pacific’s first Life Sciences Centre of Excellence. It is part of global management consulting firm LEK Consulting’s Healthcare Insights Centre and aims to drive thought leadership and innovation to elevate the life sciences ecosystem in Singapore and the region.
Dementia remains one of the biggest chronic medical issues to face families. A determination to treat the illness is a challenge that Charles Stacey, president and CEO of Singapore-based Cerecin, has grasped with both hands.
my images

Podcasts

HealthInvestor Asia twitter feed